Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.

Sezary syndrome

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies Extracorporeal Photopheresis in Sezary Syndrome Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. AEDV Registry of Primary Cutaneous Lymphoma Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients